Simplify Logo
Amgen

Amgen

Biotech company creating biologic medicines

Safety Pharmacology Senior Scientist

Full-TimeUpdated on 9/17/2026
$129.2k - $174.8k/yr

+ Annual bonus + Stock-based long-term incentives

Mid, Senior
Bachelor's, Master's, PhD
Thousand Oaks, CA, USA
In Person

About the job

Requirements
  • A doctorate degree and at least 1 year of scientific experience, or a master's degree and at least 3 years of scientific experience, or a bachelor's degree and at least 5 years of scientific experience.
  • Scientific experience relevant to nonclinical safety pharmacology.
  • Strong scientific judgment and regulatory awareness.
  • Ability to translate complex nonclinical safety pharmacology data into clear, actionable recommendations.
  • Broad experience in nonclinical safety pharmacology across cardiovascular, respiratory, and central nervous system domains.
  • Experience serving as a study director, project representative, or subject matter expert for good laboratory practice and/or non-good laboratory practice safety pharmacology studies.
  • Experience authoring or contributing to regulatory documents such as Investigator's Brochures, Investigational New Drug sections, briefing documents, or responses to regulatory questions.
Responsibilities
  • Serve as a safety pharmacology subject matter expert on cross-functional project teams and develop fit-for-purpose strategies across discovery, lead optimization, candidate selection, Investigational New Drug-enabling, and clinical development stages.
  • Design and oversee good laboratory practice and non-good laboratory practice safety pharmacology studies conducted internally or at external contract research organizations.
  • Evaluate and integrate nonclinical safety pharmacology data, including cardiovascular, respiratory, central nervous system, electrocardiogram, hemodynamic, and telemetry endpoints.
  • Integrate safety pharmacology data with toxicology, pharmacology, translational biology, drug metabolism and pharmacokinetics, clinical, and regulatory information to support weight-of-evidence decision-making.
  • Contribute to governance presentations, project-team discussions, regulatory strategy meetings, development milestone decisions, and resolution of study-related scientific or technical issues.
  • Contribute to safety pharmacology sections of regulatory documents, including Investigational New Drug-enabling summaries, Investigator's Brochures, briefing documents, responses to regulatory questions, and internal development reports.
  • Contribute to innovative safety pharmacology approaches, fit-for-purpose study designs, risk-based assessment frameworks, and translational safety strategies.
  • Monitor evolving regulatory expectations, industry best practices, scientific literature, emerging methodologies, and best practices in cardiovascular, respiratory, central nervous system, and integrated nonclinical safety assessment.
  • Participate in initiatives to improve safety pharmacology processes, templates, data standards, reporting practices, and decision frameworks.
  • Promote scientific standards, quality, and compliance across internal and external study activities.
  • Represent Amgen through scientific presentations, publications, professional societies, consortia, or cross-industry working groups.
  • Build external scientific relationships that enhance Amgen's visibility and influence in safety pharmacology.
Desired Qualifications
  • A PhD in Pharmacology, Neuroscience, Physiology, Biomedical Sciences, or a related field.
  • Experience supporting discovery and development project teams as a safety pharmacology subject matter expert or toxicology representative.
  • Experience authoring or contributing to regulatory documents such as Investigator's Brochures, Investigational New Drug sections, briefing documents, or responses to regulatory questions.
  • Strong cross-functional communication and problem-solving skills.
  • Ability to collaborate across disciplines, influence without direct authority, and manage multiple priorities in a matrixed environment.
  • A track record of scientific publications and participation in external scientific forums or consortia.

About the company

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after Q2 outperformance.
  • Repatha sales jumped 37% to $953 million, driven by cardiologist and primary-care adoption.
  • MariTide now has nine ongoing and three planned Phase 3 studies across obesity.

What critics are saying

  • Prolia and XGEVA sales fell 33% in Q2 2026 as biosimilars hit.
  • FDA proposed withdrawing TAVNEOS in April 2026, threatening a marketed rare-disease franchise.
  • If MariTide misses 2027 endpoints, Amgen loses its next obesity growth pillar.

What makes Amgen unique

  • Amgen's six growth drivers produced nearly 70% of Q2 2026 product sales.
  • IMDELLTRA sales rose 115% in Q2 2026, validating Amgen's oncology engine.
  • Hyderabad's 2027 Science and Innovation Center expands Amgen's seven-lab global R&D network.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.